Inactive Instrument

Chembio Diagnostics, Inc.

CEMI

US1635722093

CHEMBIO DIAGNOSTICS, INC. : Change in Directors or Principal Officers (form 8-K)

October 18, 2021 at 04:32 pm EDT

Item 5.02 Departure of Directors or Certain Officers; Election of Directors;


          Appointment of Certain Officers; Compensatory Arrangements of Certain
          Officers.

On October 16, 2021, Neil A. Goldman, our Executive Vice President and Chief Financial Officer, notified us that he would be terminating his employment with our company, effective on or about November 5, 2021, in order to pursue another opportunity. Mr. Goldman's resignation is not due to any disagreement with our company.

We are initiating a search process to identify and retain a successor chief financial officer.

--------------------------------------------------------------------------------

Latest news about Chembio Diagnostics, Inc.

Chembio Diagnostics, Inc. acquired FastPack® diagnostics business from Qualigen Therapeutics, Inc. for $5.8 million.	23-07-23	CI
Chembio Diagnostics, Inc.(NasdaqCM:CEMI) dropped from NASDAQ Composite Index	23-04-27	CI
Biosynex SA completed the acquisition of Chembio Diagnostics, Inc. from Perceptive Advisors LLC and others.	23-04-26	CI
Chembio Diagnostics Tender Offer Expiration Extended by Biosynex	23-04-13	MT
Chembio Diagnostics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-29	CI
Chembio Diagnostics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-29	CI
Biosynex Unit Extends Expiration Time of Tender Offer for Chembio Diagnostics Shares; Stock Rises	23-03-29	MT
Chembio Diagnostics, Inc. Auditor Raises 'Going Concern' Doubt	23-03-28	CI
Chembio Diagnostics, Inc.(NasdaqCM:CEMI) dropped from S&P TMI Index	23-03-15	CI
Chembio Announces Receipt of CLIA Waiver for its DPP HIV-Syphilis System	23-02-24	CI
Chembio Diagnostics Agrees to $17.2 Million Takeover by Biosynex; Shares Rise Pre-Bell	23-02-01	MT
Biosynex SA entered into a definitive merger agreement to acquire Chembio Diagnostics, Inc. for $17.2 million.	23-01-30	CI
Chembio Diagnostics Applies to FDA for CLIA Waiver for DPP HIV-Syphilis System	22-11-28	MT
Chembio Diagnostics, Inc. Announces FDA CLIA Waiver Submission for DPP HIV-Syphilis System	22-11-28	CI
Transcript : Chembio Diagnostics, Inc., Q3 2022 Earnings Call, Nov 03, 2022	22-11-03
Earnings Flash (CEMI) CHEMBIO DIAGNOSTICS Posts Q3 Revenue $11.2M	22-11-03	MT
Earnings Flash (CEMI) CHEMBIO DIAGNOSTICS Posts Q3 Loss $-0.21	22-11-03	MT
Chembio Diagnostics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-03	CI
Chembio Diagnostics Obtains $3.2 Million Contract to Develop Diagnostic Test for Syphilis	22-09-06	MT
Chembio Diagnostics Wins $3.2 Million Contract from the CDC for Development and Clinical Validation of Dual-Path Platform Syphilis Screen & Confirm Assay	22-09-06	CI
Chembio Diagnostics Mulling Development of Monkeypox Rapid Test; Shares Rise	22-08-16	MT
Transcript : Chembio Diagnostics, Inc., Q2 2022 Earnings Call, Aug 04, 2022	22-08-04
Earnings Flash (CEMI) CHEMBIO DIAGNOSTICS Reports Q2 Loss $-0.23	22-08-04	MT
Earnings Flash (CEMI) CHEMBIO DIAGNOSTICS Reports Q2 Revenue $9.2M	22-08-04	MT
Earnings Flash (CEMI) CHEMBIO DIAGNOSTICS Reports Q2 Loss $-0.23	22-08-04	MT

Chart Chembio Diagnostics, Inc.

Duration

Period

More charts

Company Profile

Chembio Diagnostics, Inc. is a diagnostics company. The Company is focused on developing and commercializing point-of-care tests used to detect and diagnose infectious diseases, including sexually transmitted diseases, insect vectors and tropical diseases, coronavirus disease (COVID-19), and other viral and bacterial infections, enabling expedited treatment. The Company's DPP technology offers broad market applications beyond infectious disease. The DPP platform can detect and differentiate up to eight distinct test results from a single patient sample. Its DPP Micro Reader optical analyzers can report results in approximately 15 seconds, making it well-suited for decentralized testing where real-time results enable patients to be clinically assessed while they are still on site. Its products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers.

Sector

Pharmaceuticals

More about the company